The cost-effectiveness of abatacept compared to adalimumab for adult patients with rheumatoid arthritis in the Russian Federation

Autor:	A.A. Pochuprina, A.Yu. Kulikov
Rok vydání:	2015
Předmět:	medicine.medical_specialty Adult patients Cost effectiveness business.industry Rheumatoid arthritis Internal medicine Abatacept medicine Adalimumab Russian federation medicine.disease business medicine.drug
Zdroj:	Pharmacoeconomics: theory and practice. 3:31-36
ISSN:	2312-2862
DOI:	10.30809/phe.3.2015.8
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::6a12436f8119c8442c03470982896a73 https://doi.org/10.30809/phe.3.2015.8 Zobrazit plný text záznamu